Powered by

-miRagen Therapeutics Announces Positive Data for Cobomarsen in Adult T-Cell Leukemia lymphoma Patients With Residual Disease

Jan 31, 2020 - ENP Newswire

BOULDER - miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific focus on microRNAs, today announced new efficacy and safety data from the ATLL arm of its ongoing Phase 1 clinical trial of cobomarsen, which will be presented at the 12th Annual T-Cell Lymphoma Forum in La Jolla, CA, which is taking place from January 30th to February 1st.

Of note are the data from the subtype of aggressive AT...